Neoadjuvant Therapy Improves Survival in Upfront Resectable PDAC Subtype
Key advancements have been observed within the area of cancer therapy specifically for the PDAC subtype. The usage of neoadjuvant therapy is offering significant improvement in survival rates.
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers
A noteworthy update: The FDA, on February 25th, 2026, has issued a partial clinical hold on the clinical trial of a pharmacological agent, Lorigerlimab, focused on gynecologic cancers.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma
Progress has been made within the scope of immune checkpoint inhibitor toxicities for melanoma patients. Novel management strategies are minimizing adverse impacts and improving patient outcomes.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma
Exciting breakthroughs continue in the arena of high-grade glioma treatment. SRN-101 has received a fast track designation from the FDA, accelerating its potential utilisation for patients experiencing recurrent high-grade glioma.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma
Dr. Saad Z. Usmani reported on February 25th, 2026 that a novel small molecule is displaying early activity in patients with pretreated multiple myeloma, opening up new avenues for disease management.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC
Roman Fabbricatore, on February 24th, 2026, compared the quality of life outcomes in oropharyngeal squamous cell carcinomas (OPSCC) patients after receiving either proton or photon therapy, providing patients and healthcare experts better insight into treatment benefits.
